Physician profile
Deven Dave
NPI 1023196466
$3,206.72
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,397 · 2020: $786 · 2022: $23.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $722.44 | 2019-2020 | |
| Amgen INC. | $629.39 | 2019 | |
| Lilly USA, LLC | $267.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $243.66 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $157.66 | 2019 | |
| Novo Nordisk INC | $148.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.50 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $138.52 | 2019-2020 | |
| Glaxosmithkline, LLC. | $135.06 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.62 | 2019-2020 | |
| Amarin Pharma, INC. | $121.86 | 2020 | |
| Pfizer INC. | $120.75 | 2020 | |
| Radius Health, INC. | $112.12 | 2019 | |
| Abiomed | $60.00 | 2019 | |
| Medtronic USA, INC. | $34.86 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.63 | 2019 | |
| Astellas Pharma US INC | $12.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deven Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.